Gamaleja Institute for Epidemiology and Microbiology
The Gamaleja Institute of Epidemiology and Microbiology ( Russian Национальный исследовательский центр эпидемиологии и микробиологии имени почётного академика Н. Ф. Гамалеи ) is a government research institute for immunology , virology , medical microbiology , epidemiology and biotechnology , which in the Russian capital Moscow is located.
history
The origins of the institute go back to 1891 when the Russian naturalist FM Blumenthal opened a private bacteriological laboratory. In 1919 it was nationalized and transformed into the State Bacteriological Institute of the People's Commissariat for Health of the RSFSR . In 1931 it was transformed into the Central Institute for Epidemiology and Microbiology (CIEM) of the People's Commissariat for Health of the RSFSR, in which other biochemical research institutes were merged. With the beginning of the Second World War , branches were established in Alma Ata and in what was then Sverdlovsk . A CIEM working group was also sent to Kazan. After further structural changes, in 2017 the name was changed to the Gamaleja Institute for Epidemiology and Microbiology in honor of the Russian vaccine pioneer Nikolai Gamaleja . The current director of the institute is Alexander Ginzburg.
Developed vaccines
In 2015, the Ebola vaccine GamEvac-Combi was presented, which, according to the institute , is used for infection prophylaxis in the Republic of Guinea .
On August 11, 2020, the phase 1 and 2 clinical studies for the vaccine Gam-COVID-Vac ( Russian Гам-КОВИД-Вак , alternative name Sputnik V, Russian Спутник V ) against the virus SARS-CoV- 2 were completed. This resulted in a state “registration” which, in contrast to international practice, stands between clinical phases 2 and 3 in Russia. The information on the previous scope of the clinical trial is contradictory. Despite the ongoing clinical trial, the state wants to make the vaccine available to particularly vulnerable groups such as doctors and teachers. It is argued that the vaccine is based on a long-known adenovirus platform that is successful against Ebola and MERS-CoV .
Web links
- Official Homepage (Russian)
Individual evidence
- ↑ Researchgate: Research Institute of Epidemiology and Microbiology na NF Gamalei, Russian Academy of Medical Sciences (accessed August 12, 2020)
- ↑ Information on the person in the personal database Scientific relations in the 19th century between Germany and Russia in the fields of chemistry, pharmacy and medicine , Saxon Academy of Sciences in Leipzig
- ↑ a b c Presentation of the institute's history on the official homepage (Russian, accessed on August 12, 2020)
- ↑ Вакцина от Эболы (Russian, accessed August 12, 2020)
- ↑ Vaccines to protect against Covid-19, the new coronavirus infection, accessed on August 28, 2020.
- ↑ Russia approves vaccine against SARS-CoV-2 . In: aerzteblatt.de . August 11, 2020, accessed on August 11, 2020.
- ↑ Сколько хотят заработать на прививках от коронавируса , Vedomosti.ru (accessed August 13, 2020)
- ↑ FAZ: "We can approve the vaccine earlier" (accessed on August 13, 2020)